The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2020The Role of Cannabinoid Receptor 2 in Inflammatory Responses Triggered by Alpha-synuclein
Study Rationale:
There is growing interest in the anti-inflammatory properties of cannabis-related compounds as a potential therapy for Parkinson’s disease (PD). Cannabis, or marijuana, acts on... -
Therapeutic Pipeline Program, 2020Therapeutic Swallow Sensor
Study Rationale:
Trouble swallowing is a common problem for people with Parkinson’s disease, occurring in up to 80 percent of cases. Swallowing problems can lead to drooling, increased risk of... -
Target Advancement Program, 2020Evaluating the Role of Natural Killer Cells in Parkinson's Pathology
Promising Outcomes of Original Grant:
Our original study investigated whether immune cells called human natural killer (NK) cells play a protective role on the nervous system in Parkinson’s disease... -
Therapeutic Pipeline Program, 2020Anle138b Clinical Phase 1 Studies: Food Effect, Safety and Tolerability as well as Pharmacokinetics in Parkinson´s Disease Patients
Study Rationale:
Clumps of the protein alpha-synuclein, called Lewy bodies, are a hallmark of Parkinson’s disease and a promising target for therapeutic development. Anle138b is a drug-like compound... -
Therapeutic Pipeline Program, 2020Phase II Trial of Bone Marrow-Derived Mesenchymal Stem Cells as a Disease-Modifying Therapy for Parkinson’s Disease
Study Rationale:
Chronic brain inflammation plays a critical role in the development and progression of Parkinson’s disease. This inflammation damages the brain, disrupts the blood-brain barrier, and... -
Target Advancement Program, 2020Gene Therapy Approach to Reduce Alpha‐synuclein Aggregation in a Model of Parkinson's
Study Rationale:
A hallmark of Parkinson’s disease is the accumulation of an abnormal form of the protein alpha-synuclein inside brain cells. The team plans to use a gene therapy approach to insert a...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.